ATE236628T1 - Fenofibrathaltige neue galenische arzneizusammensetzungen und ihre verwendung - Google Patents

Fenofibrathaltige neue galenische arzneizusammensetzungen und ihre verwendung

Info

Publication number
ATE236628T1
ATE236628T1 AT96401614T AT96401614T ATE236628T1 AT E236628 T1 ATE236628 T1 AT E236628T1 AT 96401614 T AT96401614 T AT 96401614T AT 96401614 T AT96401614 T AT 96401614T AT E236628 T1 ATE236628 T1 AT E236628T1
Authority
AT
Austria
Prior art keywords
fenofibrates
compositions containing
medicinal compositions
new galenic
galenic
Prior art date
Application number
AT96401614T
Other languages
English (en)
Inventor
Claude Laruelle
Original Assignee
Cll Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9481448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE236628(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cll Pharma filed Critical Cll Pharma
Application granted granted Critical
Publication of ATE236628T1 publication Critical patent/ATE236628T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT96401614T 1995-07-27 1996-07-19 Fenofibrathaltige neue galenische arzneizusammensetzungen und ihre verwendung ATE236628T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9509142A FR2737121B1 (fr) 1995-07-27 1995-07-27 Nouvelles formulations galeniques du fenofibrate et leurs applications

Publications (1)

Publication Number Publication Date
ATE236628T1 true ATE236628T1 (de) 2003-04-15

Family

ID=9481448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96401614T ATE236628T1 (de) 1995-07-27 1996-07-19 Fenofibrathaltige neue galenische arzneizusammensetzungen und ihre verwendung

Country Status (12)

Country Link
US (1) US5827536A (de)
EP (1) EP0757911B1 (de)
JP (1) JPH09328427A (de)
KR (1) KR970005285A (de)
AT (1) ATE236628T1 (de)
CA (1) CA2181422A1 (de)
DE (2) DE757911T1 (de)
ES (1) ES2110377T1 (de)
FR (1) FR2737121B1 (de)
GR (1) GR980300014T1 (de)
HU (1) HUP9602056A3 (de)
ZA (1) ZA966067B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
WO1998007414A1 (en) 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6152991A (en) 1997-04-17 2000-11-28 Praxair Technology, Inc. Multilayer adsorbent beds for PSA gas separation
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
US6264960B1 (en) 1998-11-10 2001-07-24 Sander J. Robins Treatment of vascular events using lipid-modifying compositions
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
DE19858789A1 (de) 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6838091B2 (en) * 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
EP1276465B1 (de) 2000-04-20 2014-03-12 Jagotec AG Verbessertes verfahren zur herstellung wasserunlöslicher arzneistoffpartikel
US6531158B1 (en) 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
EP1364646A4 (de) * 2001-03-01 2005-08-03 Grelan Pharmaceutical Co Fenofibrat enthaltende zusammensetzung
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE374602T1 (de) * 2001-12-21 2007-10-15 Supernus Pharmaceuticals Inc Orale kapselformulierung mit verbesserter physikalischer stabilität
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CN100594023C (zh) * 2003-02-03 2010-03-17 诺瓦提斯公司 药物制剂
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US8026281B2 (en) 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
EP1830804A2 (de) * 2004-12-06 2007-09-12 Reliant Pharmaceuticals, Inc. Stabile zusammensetzungen von fenofibrat mit fettsäureestern
CA2589654C (en) * 2004-12-06 2016-02-16 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
KR20070108945A (ko) * 2005-03-08 2007-11-13 릴라이언트 파마슈티컬스 인코퍼레이티드 스타틴과 오메가-3 지방산 및 그 조합물을 이용한 치료
JP2008534586A (ja) * 2005-03-30 2008-08-28 テバ ファーマシューティカル インダストリーズ リミティド フェノフィブレートの改良された製剤
EP1707197A1 (de) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Zusammensetzungen, welche Fenofibrat und eine Tensidmischung beinhaltet
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
EP1861084A1 (de) * 2005-03-30 2007-12-05 Teva Pharmaceutical Industries Ltd. Verbesserte fenofibratformulierungen mit menthol und/oder peg/poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
DE602005014258D1 (de) 2005-12-28 2009-06-10 Teva Pharma Pharmazeutische Formulierungen mit Fenofibrat mit verbesserter Bioverfügbarkeit
WO2010082214A2 (en) * 2008-07-03 2010-07-22 Panacea Biotec Limited Fenofibrate formulation with enhanced oral bioavailability
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN105636582A (zh) 2013-09-18 2016-06-01 乔治城大学 用非诺贝特及其类似物治疗神经退行性疾病
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (de) * 1980-11-19 1986-01-10 Laruelle Claude
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
FR2617047B1 (fr) * 1987-06-23 1991-05-10 Sanofi Sa Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate

Also Published As

Publication number Publication date
FR2737121A1 (fr) 1997-01-31
JPH09328427A (ja) 1997-12-22
HUP9602056A2 (en) 1997-06-30
DE69627253D1 (de) 2003-05-15
HU9602056D0 (en) 1996-09-30
EP0757911B1 (de) 2003-04-09
ZA966067B (en) 1997-04-07
ES2110377T1 (es) 1998-02-16
DE69627253T2 (de) 2004-01-29
CA2181422A1 (fr) 1997-01-28
DE757911T1 (de) 1998-03-26
FR2737121B1 (fr) 1997-10-03
HUP9602056A3 (en) 2000-09-28
US5827536A (en) 1998-10-27
KR970005285A (ko) 1997-02-19
EP0757911A1 (de) 1997-02-12
GR980300014T1 (en) 1998-03-31

Similar Documents

Publication Publication Date Title
ATE236628T1 (de) Fenofibrathaltige neue galenische arzneizusammensetzungen und ihre verwendung
DK1257280T3 (da) Farmaceutisk sammensætning af mikroniseret drospirenon og et östrogen til hormonsubstitutionsterapi
DK0642344T3 (da) Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering.
ATA189395A (de) Orale pharmazeutische zubereitung
GR3019298T3 (en) Pharmaceutical compositions
HUT54144A (en) Process for producing 3-desmethylmevalonic acid derivatives and pharmaceutical compositions comprising same as active ingredient
HRP20080410A2 (en) Crystalline composition containing escitalopram
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
NO912888L (no) Fremgangsmaate for fremstilling av nye peperidylethere og -thioethere.
AU661831B2 (en) 8-ene-19, 11beta -bridged steroids, their preparation and pharmaceutical formulations containing them
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
PT77309A (de) Isochinolinderivate verfahren zu ihrer herstellung pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
EP0924219A3 (de) Estrene zur Induzierung hypothalamischer Effekte
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
IL112668A (en) 4-Amino 6-substituted mycophenolic acid and derivatives thereof their preparation and pharmaceutical compositions containing them
ITMI913510A0 (it) Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
DE69215511D1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
DE69416034D1 (de) Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties